In addition, the reduced expression level of GSK3β in the liver presents concurrently with the amelioration of hepatic steatosis and fibrosis, indicating the miR-29a/GSK3β pathway acts significantly in the hepatoprotective effect. Here, GSK3B is linked to Hepatic steatosis.